Literature DB >> 27123288

Paralytic ileus due to a novel anticancer drug, nab-paclitaxel: A case report.

Xiao-Dong Jiao1, Xiu Luo2, Wen-Xing Qin1, Ling-Yan Yuan1, Yuan-Sheng Zang1.   

Abstract

Nab-paclitaxel is a recently emerged chemotherapy drug, which is widely used for the treatment of multiple types of cancer. The prospects of this novel drug are very bright as a result of its higher efficacy and lower toxicity compared with paclitaxel. Hence, the side effect, even if rare, require attention in clinical practice. The present study described an unusual case of nab-paclitaxel-associated paralytic ileus. To the best of our knowledge, this is the first report to demonstrate that nab-paclitaxel may lead to acute intestinal obstruction. Since nab-paclitaxel will be used more frequently, this unusual side effect might be encountered by a clinical oncologist and must be treated correctly. This is the first reported case, to the best of our knowledge, of paralytic ileus caused by nab-paclitaxel, which will be widely used as a novel anticancer drug.

Entities:  

Keywords:  complication; nab-paclitaxel; paralytic ileus

Year:  2016        PMID: 27123288      PMCID: PMC4840571          DOI: 10.3892/mco.2016.782

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  17 in total

Review 1.  Safety and efficacy evaluation of albumin-bound paclitaxel.

Authors:  Sara Cecco; Maria Aliberti; Paolo Baldo; Elisa Giacomin; Roberto Leone
Journal:  Expert Opin Drug Saf       Date:  2014-02-22       Impact factor: 4.250

2.  In vivo effect of methylcobalamin on the peripheral nerve structure in streptozotocin diabetic rats.

Authors:  S Yagihashi; A Tokui; H Kashiwamura; S Takagi; K Imamura
Journal:  Horm Metab Res       Date:  1982-01       Impact factor: 2.936

3.  Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab.

Authors:  Hassan T Rahman; Steven Yeh; Chris S Bergstrom
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-12       Impact factor: 2.671

Review 4.  nab-Paclitaxel mechanisms of action and delivery.

Authors:  Denise A Yardley
Journal:  J Control Release       Date:  2013-06-11       Impact factor: 9.776

5.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

6.  Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.

Authors:  Prakash Vishnu; Vivek Roy
Journal:  Breast Cancer (Auckl)       Date:  2011-04-13

7.  A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).

Authors:  Wasaburo Koizumi; Satoshi Morita; Yuh Sakata
Journal:  Jpn J Clin Oncol       Date:  2014-12-16       Impact factor: 3.019

Review 8.  Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.

Authors:  Edgardo Rivera; Mary Cianfrocca
Journal:  Cancer Chemother Pharmacol       Date:  2015-01-18       Impact factor: 3.333

9.  Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.

Authors:  Denise A Yardley; Lowell Hart; Linda Bosserman; Mansoor N Salleh; David M Waterhouse; Maura K Hagan; Paul Richards; Michelle L DeSilvio; Janine M Mahoney; Yasir Nagarwala
Journal:  Breast Cancer Res Treat       Date:  2012-12-08       Impact factor: 4.872

10.  Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.

Authors:  Andrea Casadei Gardini; Michele Aquilina; Devil Oboldi; Alessandro Lucchesi; Silvia Carloni; Elena Tenti; Marco Angelo Burgio; Dino Amadori; Giovanni Luca Frassineti
Journal:  BMC Cancer       Date:  2013-11-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.